Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine

The coronavirus disease 2019 (COVID‐19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID‐19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanamori, Hikaru, Sawada, Yu, Sato, Sayaka, Hara, Reiko, Minokawa, Yoko, Sugino, Hitomi, Saito‐Sasaki, Natsuko, Yamamoto, Kayo, Okada, Etsuko, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349828/
http://dx.doi.org/10.1002/cia2.12248
_version_ 1784762156067061760
author Nanamori, Hikaru
Sawada, Yu
Sato, Sayaka
Hara, Reiko
Minokawa, Yoko
Sugino, Hitomi
Saito‐Sasaki, Natsuko
Yamamoto, Kayo
Okada, Etsuko
Nakamura, Motonobu
author_facet Nanamori, Hikaru
Sawada, Yu
Sato, Sayaka
Hara, Reiko
Minokawa, Yoko
Sugino, Hitomi
Saito‐Sasaki, Natsuko
Yamamoto, Kayo
Okada, Etsuko
Nakamura, Motonobu
author_sort Nanamori, Hikaru
collection PubMed
description The coronavirus disease 2019 (COVID‐19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID‐19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated with concerns, such as vaccine‐associated adverse reactions, which are currently highlighted issues for clinicians. We experienced two cases of mild cutaneous adverse reaction following COVID‐19 vaccine administration, which was successfully controlled by prior administration of the antihistamine agent fexofenadine 3 days before COVID‐19 vaccination for 7 days.
format Online
Article
Text
id pubmed-9349828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93498282022-08-04 Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine Nanamori, Hikaru Sawada, Yu Sato, Sayaka Hara, Reiko Minokawa, Yoko Sugino, Hitomi Saito‐Sasaki, Natsuko Yamamoto, Kayo Okada, Etsuko Nakamura, Motonobu Journal of Cutaneous Immunology and Allergy Case Studies The coronavirus disease 2019 (COVID‐19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID‐19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated with concerns, such as vaccine‐associated adverse reactions, which are currently highlighted issues for clinicians. We experienced two cases of mild cutaneous adverse reaction following COVID‐19 vaccine administration, which was successfully controlled by prior administration of the antihistamine agent fexofenadine 3 days before COVID‐19 vaccination for 7 days. John Wiley and Sons Inc. 2022-07-06 /pmc/articles/PMC9349828/ http://dx.doi.org/10.1002/cia2.12248 Text en © 2022 The Authors. Journal of Cutaneous Immunology and Allergy published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Studies
Nanamori, Hikaru
Sawada, Yu
Sato, Sayaka
Hara, Reiko
Minokawa, Yoko
Sugino, Hitomi
Saito‐Sasaki, Natsuko
Yamamoto, Kayo
Okada, Etsuko
Nakamura, Motonobu
Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
title Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
title_full Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
title_fullStr Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
title_full_unstemmed Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
title_short Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
title_sort prior antihistamine agent successfully impaired cutaneous adverse reactions to covid‐19 vaccine
topic Case Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349828/
http://dx.doi.org/10.1002/cia2.12248
work_keys_str_mv AT nanamorihikaru priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT sawadayu priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT satosayaka priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT harareiko priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT minokawayoko priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT suginohitomi priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT saitosasakinatsuko priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT yamamotokayo priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT okadaetsuko priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine
AT nakamuramotonobu priorantihistamineagentsuccessfullyimpairedcutaneousadversereactionstocovid19vaccine

Ejemplares similares